腎細胞癌治療薬の世界市場予測・分析

◆英語タイトル:PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023
◆商品コード:GDHC88PIDR
◆発行会社(調査会社):GlobalData
◆発行日:2016年4月21日
◆ページ数:322
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD10,995 ⇒換算¥1,253,430見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD21,990 ⇒換算¥2,506,860見積依頼/購入/質問フォーム
Enterprisewide License(複数国内共有可)USD32,985 ⇒換算¥3,760,290見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※レポート購入後、該当レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。



当調査レポートでは、腎細胞癌治療薬の世界市場について調査・分析し、以下の構成でお届けいたします。
・イントロダクション
・腎細胞癌の概要:病因、病態生理、症状
・疫学:リスク要因、併存症、グローバル動向、予測方法、疫学的予測結果
・腎細胞癌の管理:治療概要、主要国における診断、診療状況
・腎細胞癌治療薬の競争状況:製品概要、主要医薬品ブランド分析
・腎細胞癌治療薬市場機会及びアンメット・ニーズ分析
・腎細胞癌治療薬のパイプライン分析:主要国別治験動向、フェーズ別/進捗状況別治験動向、有望な薬剤
・製薬企業動向:戦略動向、主要企業情報
・腎細胞癌治療薬市場展望:世界市場及び主要国の市場規模予測、成長要因、阻害要因
【レポートの概要】

PharmaPoint: Renal Cell Carcinoma – Global Drug Forecast and Market Analysis to 2023

Summary

Renal cell carcinoma (RCC) is among the 10 most frequently occurring cancers in Western countries. The RCC market is currently dominated by anti-angiogenic agents and tyrosine kinase inhibitors (TKIs) in particular, but it will experience dramatic changes over the forecast period as patents expire and promising new therapies enter the market. A large share of the RCC market is currently dominated by a few large companies, but they will struggle to retain these shares as they are joined by new entrants. One of these new entrants, Opdivo, is expected to have the largest market share by 2023. The different lines of treatment will offer up different battlegrounds and niches for companies, large and small, to compete for. The battle for the first-line of therapy is expected to be fierce, with three programmed death protein 1 (PD-1)/programmed death ligand 1 (PD-L1)-containing combination therapies backed by large companies lining up to compete. Out of this competition, new standards of care are expected to emerge for the different lines of treatment. There will also be a number of unmet needs still remaining at the end of the forecast period, and with that, the opportunity for pipeline drugs to carve out a niche in the RCC space.

Highlights

Key Questions Answered

- The RCC market is marked by the presence of a number of unmet needs. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of RCC market?
- The late-stage RCC pipeline has therapies targeting different lines of therapy. Which drugs will have the biggest impact in each RCC setting? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
- Current therapies used to treat RCC include tyrosine kinase inhibitors and mTOR inhibitors. What will be the impact of the patent expiry of the current standard of care? How will the advent of new therapies change the drug treatment landscape for RCC? How will new drug combinations change the treatment paradigm of RCC? What are the key drivers and barriers to this change?

Key Findings

- The main drivers of the growth of the RCC market will be the launch of Opdivo in second-line setting and PD-1 modulator combinations in the first-line setting. GlobalData forecasts significant patient uptake for Opdivo, which will supersede tyrosine kinase inhibitors and mTOR inhibitors to become the SoC in second-line setting.
- The approval of immunotherapy in monotherapy or in combination with other agents will partially fulfil key unmet needs in the RCC space: however, many of these unmet needs will still remain even after these agents are launched.
- Another driver of the RCC market is the increasing incidence of RCC cases within the 8MM. The biggest constrainer of the RCC market is the launch of generics of tyrosine kinase inhibitors currently established as standard of care in most markets.

Scope

- Overview of RCC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized RCC therapeutics market revenue, average cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the RCC therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global RCC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to –
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the global RCC therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RCC therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global RCC therapeutics market from 2013-2023.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

【レポートの目次】

1 Table of Contents
1 Table of Contents 8
1.1 List of Tables 15
1.2 List of Figures 21
2 Introduction 24
2.1 Catalyst 24
2.2 Related Reports 24
2.3 Upcoming Related Reports 25
3 Disease Overview 26
3.1 Etiology and Pathophysiology 26
3.1.1 Etiology 26
3.1.2 Pathophysiology 26
3.2 Clinical Staging 27
3.3 Symptoms 28
3.4 Prognostic Models 29
3.5 Potential Biomarkers 30
4 Epidemiology 31
4.1 Disease Background 31
4.2 Risk Factors and Comorbidities 31
4.3 Global Trends 33
4.3.1 Incidence 33
4.3.2 Survival Rates for RCC – 8MM 35
4.4 Forecast Methodology 36
4.4.1 Sources Used 38
4.4.2 Sources Not Used 41
4.4.3 Forecast Assumptions and Methods for RCC Diagnosed Incident Cases 41
4.4.4 Forecast Assumptions and Methods for RCC Five-Year Diagnosed Prevalent Cases 42
4.4.5 Forecast Assumptions and Methods for RCC by Clinical Stage at Diagnosis 43
4.5 Epidemiological Forecast of RCC (2013-2023) 44
4.5.1 Diagnosed Incident Cases of RCC 44
4.5.2 Age-Specific Diagnosed Incident Cases of RCC 45
4.5.3 Sex-Specific Diagnosed Incident Cases of RCC 47
4.5.4 Age-Standardized Diagnosed Incidence of RCC 49
4.5.5 Diagnosed Incident Cases of RCC by Clinical Stage at Diagnosis 51
4.5.6 Five-Year Diagnosed Prevalent Cases of RCC 52
4.6 Discussion 53
4.6.1 Epidemiological Forecast Insight 53
4.6.2 Limitations of the Analysis 54
4.6.3 Strengths of the Analysis 54
5 Disease Management 56
5.1 Diagnosis and Treatment Overview 56
5.1.1 Screening and Diagnosis 56
5.1.2 Surgical Management of RCC 56
5.1.3 Treatment Guidelines and Leading Prescribed Drugs 57
5.1.4 Clinical Practice 59
5.2 US 64
5.2.1 Diagnosis and Surgical Management 64
5.2.2 Clinical Practice (Drug Treatment) 65
5.3 France 66
5.3.1 Diagnosis and Surgical Management 66
5.3.2 Clinical Practice (Drug Treatment) 67
5.4 Germany 67
5.4.1 Diagnosis and Surgical Management 68
5.4.2 Clinical Practice (Drug Treatment) 68
5.5 Italy 69
5.5.1 Diagnosis and Surgical Management 69
5.5.2 Clinical Practice (Drug Treatment) 70
5.6 Spain 71
5.6.1 Diagnosis and Surgical Management 71
5.6.2 Clinical Practice (Drug Treatment) 72
5.7 UK 73
5.7.1 Diagnosis and Surgical Management 73
5.7.2 Clinical Practice (Drug Treatment) 74
5.8 Japan 75
5.8.1 Diagnosis and Surgical Management 75
5.8.2 Clinical Practice (Drug Treatment) 76
5.9 China 77
5.9.1 Diagnosis and Surgical Management 78
5.9.2 Clinical Practice (Drug Treatment) 78
6 Competitive Assessment 79
6.1 Overview 79
6.2 Product Profiles – Major Brands 79
6.2.1 Sutent (sunitinib) 79
6.2.2 Nexavar (sorafenib) 87
6.2.3 Votrient (pazopanib) 93
6.2.4 Avastin (bevacizumab) 101
6.2.5 Torisel (temsirolimus) 106
6.2.6 Inlyta (axitinib) 112
6.2.7 Afinitor (everolimus) 118
6.2.8 Interferon-alfa 123
6.2.9 Interleukin-2 126
6.2.10 Tarceva (erlotinib) 128
7 Unmet Needs and Opportunities 130
7.1 Overview 130
7.2 Challenge the Resistance to Metastatic RCC Treatments With New Targeted Agents Improving the Survival of Metastatic RCC Patients 130
7.2.1 Unmet Need 130
7.2.2 Gap Analysis 131
7.2.3 Opportunity 132
7.3 Drugs With Improved Tolerability Profiles 133
7.3.1 Unmet Need 133
7.3.2 Gap Analysis 133
7.3.3 Opportunity 135
7.4 More Efficacious Therapies for the Treatment of Unfavorable Risk Metastatic RCC 135
7.4.1 Unmet Need 135
7.4.2 Gap Analysis 136
7.4.3 Opportunity 136
7.5 Targeted Therapies for Non-Clear Cell RCC 137
7.5.1 Unmet Need 137
7.5.2 Gap Analysis 138
7.5.3 Opportunity 139
7.6 Novel Adjuvant Therapies for Non-Metastatic RCC 140
7.6.1 Unmet need 140
7.6.2 Gap Analysis 140
7.6.3 Opportunity 142
7.7 Biomarkers 143
7.7.1 Overview 143
7.7.2 Gap Analysis 143
7.7.3 Opportunity 145
8 Pipeline Assessment 147
8.1 Overview 147
8.2 Promising Drugs in Clinical Development 148
8.2.1 Opdivo (nivolumab) and Yervoy (ipilimumab) 151
8.2.2 Atezolizumab 161
8.2.3 Cometriq (cabozantinib) 168
8.2.4 IMA901 175
8.2.5 AGS-003 (rocapuldencel-t) 177
8.2.6 Tivozanib 183
8.2.7 Lenvima (lenvatinib) 191
8.2.8 Avelumab 196
9 Promising Approaches in Early-Stage Development 202
9.1 Keytruda (pembrolizumab) 202
9.1.1 Overview 202
9.2 Dalantercept (ACE-041) 203
9.2.1 Overview 203
9.3 Archexin (RX-021) 203
9.3.1 Overview 203
9.4 Other Drugs in Development 203
10 Current and Future Players 205
10.1 Overview 205
10.2 Trends in Corporate Strategy 207
10.3 Company Profiles 208
10.3.1 Pfizer 208
10.3.2 Novartis 212
10.3.3 Bayer 213
10.3.4 Roche 215
10.3.5 Bristol-Myers Squibb 218
10.3.6 Merck & Co. 220
10.3.7 Exelixis 222
10.3.8 Eisai 223
10.3.9 AVEO Oncology 225
10.3.10 Argos Therapeutics 227
11 Market Outlook 230
11.1 Global Markets 230
11.1.1 Forecast 230
11.1.2 Drivers and Barriers – Global Issues 236
11.2 US 239
11.2.1 Forecast 239
11.2.2 Key Events 244
11.2.3 Drivers and Barriers 245
11.3 5EU 246
11.3.1 Forecast 246
11.3.2 Key Events 251
11.3.3 Drivers and Barriers 252
11.4 Japan 253
11.4.1 Forecast 253
11.4.2 Key Events 257
11.4.3 Drivers and Barriers 257
11.5 China 259
11.5.1 Forecast 259
11.5.2 Key Events 263
11.5.3 Drivers and Barriers 263
12 Appendix 265
12.1 Bibliography 265
12.2 Abbreviations 289
12.3 Methodology 295
12.4 Forecasting Methodology 295
12.4.1 Diagnosed RCC Patients 295
12.4.2 Percent Drug-Treated Patients 296
12.4.3 Drugs Included in Each Therapeutic Class 297
12.4.4 Launch and Patent Expiration Dates 298
12.4.5 General Pricing Assumptions 299
12.4.6 Average Body Weight and Surface Area Across the 8MM 300
12.4.7 General Forecast Assumptions 300
12.4.8 Individual Drug Assumptions 301
12.4.9 Generic Erosion 307
12.4.10 Pricing of Pipeline Agents 307
12.5 Primary Research – KOLs Interviewed for This Report 314
12.6 Primary Research – High-Prescribers Surveyed for this Report 316
12.7 About the Authors 317
12.7.1 Author 317
12.7.2 Epidemiologist 318
12.7.3 Therapy Director 319
12.7.4 Global Director of Therapy Analysis and Epidemiology 319
12.7.5 Global Head of Healthcare 320
12.8 About GlobalData 321
12.9 Disclaimer 321

1.1 List of Tables
Table 1: Classifications of RCC 27
Table 2: TNM and Staging Classification System for RCC 28
Table 3: Symptoms of RCC 29
Table 4: Risk Factors and Comorbidities for RCC 32
Table 5: Trends in the Age-Adjusted Incidence of Kidney Cancers in the US, Ages ≥20 Years, 1993-2007 33
Table 6: Trends in the Age-Adjusted Incidence of Kidney Cancers in the 5EU, Ages ≥20 Years, 1993-2007 34
Table 7: Trends in the Age-Adjusted Incidence of Kidney Cancers in Japan, Ages ≥20 Years, 1993-2007 34
Table 8: Trends in the Age-Adjusted Incidence of Kidney Cancers in Urban China, Ages ≥20 Years, 1993-2007 35
Table 9: Trends in the Five-Year Relative Survival (%) of Kidney Cancers in the 8MM, Both Sexes, 1993-2007 36
Table 10: 8MM, Sources of Epidemiological Data Used for the Forecast for RCC Diagnosed Incident Cases 37
Table 11: 8MM, Sources of Epidemiological Data Used for the Forecast for RCC Diagnosed Five-Year Prevalent Cases 37
Table 12: 8MM, Sources of Epidemiological Data Used for the Segmentation of RCC Incident Cases by Clinical Stage at Diagnosis 38
Table 13: 8MM, Diagnosed Incident Cases of RCC, Both Sexes, Ages ≥20 Years, N, 2013-2023 44
Table 14: 8MM, Age-Specific Diagnosed Incident Cases of RCC, Both Sexes, N (Row %), 2013 46
Table 15: 8MM, Sex-Specific Diagnosed Incident Cases of RCC, Ages ≥20 Years, N (Row %), 2013 48
Table 16: 8MM, Five-Year Diagnosed Prevalent Cases of RCC, Both Sexes, Ages ≥20 Years, N, 2013-2023 52
Table 17: Treatment Guidelines for RCC 58
Table 18: Most Prescribed Drugs for RCC by Class in the 8MM 59
Table 19: Country Profile - US 64
Table 20: Country Profile - France 66
Table 21: Country Profile - Germany 67
Table 22: Country Profile - Italy 69
Table 23: Country Profile - Spain 71
Table 24: Country Profile - UK 73
Table 25: Country Profile - Japan 75
Table 26: Country Profile - China 77
Table 27: Leading Treatments for RCC, 2015 79
Table 28: Product Profile - Sutent (sunitinib) 80
Table 29: Results of the Trial Comparing Sutent Versus IFN-alfa 83
Table 30: Summary of AEs from the Trial of Sutent Versus IFN-alfa 85
Table 31: Sutent SWOT Analysis, 2014 86
Table 32: Global Sales Forecasts ($m) for Sutent 2013-2023 87
Table 33: Product Profile - Nexavar (sorafenib) 88
Table 34: Results of the Trial Comparing Nexavar Versus Placebo 90
Table 35: Summary of AEs from the Trial of Nexavar versus Placebo 91
Table 36: Nexavar SWOT Analysis, 2014 92
Table 37: Global Sales Forecast ($m) for Nexavar, 2013-2023 93
Table 38: Product Profile - Votrient (pazopanib) 94
Table 39: Results of the Trial Comparing Votrient Versus Placebo 96
Table 40: Summary of the Results of the Trials Comparing Votrient Versus Sutent 97
Table 41: Summary of AEs from the Trial of Votrient Versus Sutent 99
Table 42: Votrient SWOT Analysis, 2014 100
Table 43: Global Sales Forecast ($m) for Votrient, 2013-2023 101
Table 44: Product Profile - Avastin (bevacizumab) 102
Table 45: Results of the Trial Comparing Avastin + IFN-alfa Versus IFN-alfa + Placebo 103
Table 46: Summary of AEs from the Trial of Avastin + IFN-alfa Versus IFN-alfa + placebo 104
Table 47: Avastin SWOT Analysis, 2014 105
Table 48: Global Sales Forecasts ($m) for Avastin, 2013-2023 106
Table 49: Product Profile - Torisel (temsirolimus) 107
Table 50: Results of the Trial Comparing Torisel Versus IFN-alfa Versus Torisel + IFN-alfa 108
Table 51: Summary of AEs from the Trial Comparing Torisel Versus IFN-alfa Versus Torisel + IFN-alfa 110
Table 52: Torisel SWOT Analysis, 2014 111
Table 53: Global Sales Forecasts ($m) for Torisel, 2013-2023 112
Table 54: Product Profile - Inlyta (axitinib) 113
Table 55: Results of the Trial Comparing Inlyta Versus Nexavar 115
Table 56: Summary of AEs from the Trial Comparing Inlyta Versus Nexavar 116
Table 57: Inlyta SWOT Analysis, 2014 117
Table 58: Global Sales Forecasts ($m) for Inlyta, 2013-2023 118
Table 59: Product Profile - Afinitor (everolimus) 119
Table 60: Results of the Record-1 Trial Comparing Afinitor Versus Placebo 120
Table 61: Summary of AEs from the Trial Comparing Afinitor Versus Placebo 121
Table 62: Afinitor SWOT Analysis 122
Table 63: Global Sales Forecasts ($m) for Afinitor, 2013-2023 123
Table 64: Results of the Trial Comparing IFN-alfa Versus IFN-alfa + vinblastine 124
Table 65: Summary of AEs from the Trial of IFN-alfa 125
Table 66: Results of the Trial Comparing High-Dose IL-2 Versus IL-2 + IFN-alfa 127
Table 67: Summary of AEs from the High-Dose IL-2 Versus IL-2 + IFN-alfa Trial 128
Table 68: Selected placebo-controlled, randomized adjuvant RCC trials 141
Table 69: Comparison of Therapeutic Classes in Development for RCC, 2016 151
Table 70: Product Profile - Opdivo (nivolumab) 152
Table 71: Product Profile - Yervoy (imilimumab) 152
Table 72: Efficacy of Opdivo in the CheckMate 025 Trial 154
Table 73: Efficacy of Opdivo + Yervoy, Opdivo + Stutent, and Opdivo + Votrient 156
Table 74: Safety of Opdivo and Afinitor from the CheckMate 025 Trial 157
Table 75: Safety Profile of Opdivo + Yervoy, Opdivo + Sutent, and Opdivo + Votrient 158
Table 76: Opdivo (monotherapy or combination with Yervoy) SWOT Analysis, 2016 160
Table 77: Global Sales Forecasts ($M) for Opdivo, 2013-2023 161
Table 78: Product Profile - Atezolizumab 162
Table 79: Efficacy of Atezolizumab 164
Table 80: Efficacy of Atezolizumab + Avastin combination therapy 164
Table 81: Safety of Atezolizumab in Phase Ib Study 165
Table 82: Atezolizumab SWOT Analysis, 2016 167
Table 83: Global Sales Forecasts ($M) for Atezolizumab, 2013-2023 168
Table 84: Product Profile - Cometriq (cabozantinib) 169
Table 85: Efficacy of Cometriq in the Phase III METEOR Trial 171
Table 86: Safety of Cometriq 172
Table 87: Cometriq SWOT Analysis, 2016 174
Table 88: Global Sales Forecasts ($M) for Cometriq, 2013-2023 175
Table 89: Product Profile - IMA901 176
Table 90: Efficacy of IMA901 in the Phase III IMPRINT Trial 176
Table 91: Product Profile - AGS-003 178
Table 92: AGS-003 SWOT Analysis, 2016 182
Table 93: Global Sales Forecasts ($M) for AGS-003, 2013-2023 183
Table 94: Product Profile - Tivozanib 185
Table 95: Efficacy of Tivozanib 186
Table 96: Safety of Tivozanib 187
Table 97: Safety profile of Tivozanib over time 188
Table 98: Tivozanib SWOT Analysis, 2016 190
Table 99: Global Sales Forecasts ($M) for Tivozanib, 2013-2023 191
Table 100: Product Profile - Lenvima (lenvatinib) 192
Table 101: Efficacy of Lenvima 193
Table 102: Lenvima SWOT Analysis, 2016 195
Table 103: Global Sales Forecasts ($M) for Lenvima, 2013-2023 196
Table 104: Product Profile - Avelumab 197
Table 105: Avelumab (in combination with Inlyta) SWOT Analysis, 2016 200
Table 106: Global Sales Forecasts ($M) for Avelumab, 2013-2023 201
Table 107: Drug Candidates in Early Development, 2016 204
Table 108: Key Companies in the RCC Market in the 8MM, 2013-2023 205
Table 109: Pfizer’s RCC Portfolio Assessment, 2016 210
Table 110: Novartis’ RCC Portfolio Assessment, 2016 212
Table 111: Bayer’s RCC Portfolio Assessment, 2016 214
Table 112: Roche’s RCC Portfolio Assessment, 2016 216
Table 113: BMS’ RCC Portfolio Assessment, 2016 219
Table 114: Merck & Co.’s RCC Portfolio Assessment, 2016 220
Table 115: Exelixis’ RCC Portfolio Assessment, 2016 222
Table 116: Eisai RCC Portfolio Assessment, 2016 224
Table 117: AVEO Oncology’s RCC Portfolio Assessment, 2016 226
Table 118: Argos Therapeutics’ RCC Portfolio Assessment, 2016 228
Table 119: Sales Forecasts ($m) for Renal Cell Carcinoma in the Global Markets, 2013-2023 230
Table 120: RCC Market Drivers and Barriers, 2013-2023 236
Table 121: Sales Forecasts ($m) for Renal Cell Carcinoma in the United States, 2013-2023 240
Table 122: Key Events Impacting Sales for RCC in the US, 2016 244
Table 123: US RCC Market Drivers and Barriers, 2016 245
Table 124: Sales Forecasts ($m) for Renal Cell Carcinoma in 5EU, 2013-2023 247
Table 125: Key Events Impacting Sales for RCC in 5EU, 2016 251
Table 126: 5EU RCC Market Drivers and Barriers, 2016 252
Table 127: Sales Forecasts ($m) for Renal Cell Carcinoma in Japan, 2013-2023 254
Table 128: Key Events Impacting Sales for RCC in Japan, 2016 257
Table 129: Japan RCC Market - Drivers and Barriers, 2016 257
Table 130: Sales Forecasts ($m) for Renal Cell Carcinoma in China, 2013-2023 260
Table 131: Key Events Impacting Sales for RCC in China, 2016 263
Table 132: China RCC Market - Drivers and Barriers, 2016 263
Table 133: RCC Incidence, 2013-2023 296
Table 134: RCC, Key Launch Dates 298
Table 135: RCC, Key Patent Expiries 298
Table 136: Average Body Weight and Surface Area Across the 8MM 300
Table 137: Average Cost of Therapy of Sutent 302
Table 138: Average Cost of Therapy of Votrient 303
Table 139: Average Cost of Therapy of Nexavar 304
Table 140: Average Cost of Therapy of Avastin 304
Table 141: Average Cost of Therapy of Inlyta 305
Table 142: Average Cost of Therapy of Torisel 306
Table 143: Average Cost of Therapy of Afinitor 307
Table 144: Average Cost of Therapy of Opdivo 308
Table 145: Average Cost of Therapy of Yervoy + Opdivo 308
Table 146: Average Cost of Therapy of Atezolizumab 309
Table 147: Average Cost of Therapy of Avelumab 310
Table 148: Average Cost of Therapy of Cometriq 311
Table 149: Average Cost of Therapy of Lenvima 312
Table 150: Average Cost of Therapy of tivozanib 312
Table 151: Average Cost of Therapy of AGS-003 313
Table 152: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 316

1.2 List of Figures
Figure 1: 8MM, Diagnosed Incident Cases of RCC, Both Sexes, Ages ≥20 Years, N, 2013-2023 45
Figure 2: 8MM, Age-Specific Diagnosed Incident Cases of RCC, Both Sexes, N, 2013 47
Figure 3: 8MM, Sex-Specific Diagnosed Incident Cases of RCC, Ages ≥20 Years, N, 2013 49
Figure 4: 8MM, Age-Standardized Diagnosed Incidence of RCC (Cases per 100,000 Population), Ages ≥20 Years, by Sex, 2013 50
Figure 5: 8MM, Diagnosed Incident Cases of RCC by Clinical Stage at Diagnosis, Ages ≥20 Years, N, 2013 51
Figure 6: 8MM, Five-Year Diagnosed Prevalent Cases of RCC, Both Sexes, Ages ≥20 Years, N, 2013-2023 53
Figure 7: Treatment Algorithm for RCC 63
Figure 8: RCC - Phase III Pipeline, 2013-2023 149
Figure 9: Competitive Assessment of Late-Stage Pipeline Agents in RCC, 2013-2023 150
Figure 10: Opdivo’s Development in RCC 154
Figure 11: Clinical and Commercial Positioning of Opdivo 159
Figure 12: Atezolizumab’s Development in RCC 162
Figure 13: Clinical and Commercial Positioning of Atezolizumab 166
Figure 14: Cometriq’s Development in RCC 170
Figure 15: Clinical and Commercial Positioning of Cometriq 173
Figure 16: AGS-003’s Development in RCC 179
Figure 17: Clinical and Commercial Positioning of AGS-003 181
Figure 18: Tivozanib’s Development in RCC 185
Figure 19: Clinical and Commercial Positioning of Tivozanib 189
Figure 20: Lenvima’s Development in RCC 192
Figure 21: Clinical and Commercial Positioning of Lenvima 194
Figure 22: Avelumab’s Development in RCC 198
Figure 23: Clinical and Commercial Positioning of Avelumab 199
Figure 24: Global Sales of Branded Products for aRCC by Company, 2013-2023 206
Figure 25: Company Portfolio Gap Analysis in RCC, 2013-2023 207
Figure 26: Pfizer SWOT Analysis in RCC, 2014 211
Figure 27: Novartis SWOT Analysis in RCC, 2014 213
Figure 28: Bayer SWOT Analysis in RCC, 2014 215
Figure 29: Roche SWOT Analysis in RCC, 2014 217
Figure 30: Bristol-Myers Squibb SWOT Analysis in RCC, 2014 219
Figure 31: Merck & Co SWOT Analysis in RCC, 2014 221
Figure 32: Exelexis SWOT Analysis in RCC, 2014 223
Figure 33: Eisai SWOT Analysis in RCC, 2014 225
Figure 34: AVEO Oncology SWOT Analysis in RCC, 2014 227
Figure 35: Argos Therapeutics SWOT Analysis in RCC, 2014 229
Figure 36: Global Sales for aRCC by Region, 2013-2023 233
Figure 37: Global sales for aRCC by Class, 2013-2023 234
Figure 38: Global Sales for aRCC by Brand, 2013-2023 235
Figure 39: Sales for aRCC in the US by Class, 2013-2023 242
Figure 40: Sales for aRCC in the US by Brand, 2013-2023 243
Figure 41: Sales for aRCC in the 5EU by Class, 2013-2023 249
Figure 42: Sales for aRCC in 5EU by Brand, 2013-2023 250
Figure 43: Sales for aRCC in the Japan by Class, 2013-2023 255
Figure 44: Sales for aRCC in Japan by Brand, 2013-2023 256
Figure 45: Sales for aRCC in the China by Class, 2013-2023 261
Figure 46: Sales for aRCC in China by Brand, 2013-2023 262

【掲載企業】

Pfizer
Novartis
Bayer
Roche
Bristol-Myers Squibb
Merck & Co.
Exelixis
Eisai
AVEO Oncology
Argos Therapeutics

【レポートのキーワード】

腎細胞癌

【免責事項】
※当レポート上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当レポートに記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当レポート上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチ(株)はその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチ(株)が翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

★調査レポート[腎細胞癌治療薬の世界市場予測・分析]についてメールでお問い合わせはこちら


※世界の市場調査資料 総合販売サイトMarketReport.jpはH&Iグローバルリサーチ株式会社が運営しております。海外進出、グローバル事業戦略策定、新規事業機会の発掘、競合他社の動向把握などに必要な情報やインサイトをお客様にご提供しております。H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。
※当サイトでは2016年12月10日現在 219,328 件の調査レポートを取り扱っております。当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。

◆H&Iグローバルリサーチのお客様(例)◆